欧盟HMA药品数据库（European Union HMA Authorisation of Medicines DataBase）
MR编号
IE/H/0157/001
药品名称
Lipantil Supra 215 mg, film-coated tablet.
活性成分
fenofibrate 215.0 mg
剂型
Film-coated tablet
上市许可持有人
Mylan IRE Healthcare Limited, Unit 35/36, Grange Parade, Baldoyle Industrial Estate, Dublin 13, Ireland
参考成员国 - 产品名称
Ireland (IE)
互认成员国 - 产品名称
Poland (PL)
Czechia (CZ)
Slovakia (SK)
许可日期
2005/07/10
最近更新日期
2024/03/04
药物ATC编码
C10AB05 fenofibrate
申请类型
TypeLevel1：
Known Active Substance
TypeLevel2：
Initial Application
TypeLevel3：
Full Dossier [Article 8.3(i)]
TypeLevel4：
Chemical Substance
TypeLevel5：
Prescription Only
附件文件下载
Final PL
|
common_pl_annotated_fenofibrate 145 mg_WS_Feb 2017final
Date of last change:2024/09/06
Final PL
|
common_pl_annotated_fenofibrate 160 mg_WS_Feb 2017final
Date of last change:2024/09/06
Final PL
|
common_pl_annotated_fenofibrate 200mg_WS_Feb 2017final
Date of last change:2024/09/06
Final PL
|
common_pl_annotated_fenofibrate 215 mg_WS_Feb 2017final
Date of last change:2024/09/06
Final PL
|
common_pl_annotated_fenofibrate 67mg_WS_Feb 2017final
Date of last change:2024/09/06
Final PL
|
common_pl_clean_fenofibrate 145 mg_WS_Feb 2017final
Date of last change:2024/09/06
Final PL
|
common_pl_clean_fenofibrate 160 mg_WS_Feb 2017final
Date of last change:2024/09/06
Final PL
|
common_pl_clean_fenofibrate 200mg_WS_Feb 2017final
Date of last change:2024/09/06
Final PL
|
common_pl_clean_fenofibrate 215 mg_WS_Feb 2017final
Date of last change:2024/09/06
Final PL
|
common_pl_clean_fenofibrate 67mg_WS_Feb 2017final
Date of last change:2024/09/06
Final SPC
|
common_spc_annotated_feno 145 mg_WS_Feb 2017final
Date of last change:2024/09/06
Final SPC
|
common_spc_annotated_fenofibrate 200mg_WS_Feb 2017final
Date of last change:2024/09/06
Final SPC
|
common_spc_annotated_fenofibrate 215 mg_WS_Feb 2017final
Date of last change:2024/09/06
Final SPC
|
common_spc_annotated_fenofibrate 67mg_WS_Feb 2017final
Date of last change:2024/09/06
Final SPC
|
common_spc_annotated_fenofibrate_160mg_WS_Feb 2017final
Date of last change:2024/09/06
Final SPC
|
common_spc_clean_fenofibrate 145 mg_WS_Feb 2017final
Date of last change:2024/09/06
Final SPC
|
common_spc_clean_fenofibrate 200mg_WS_Feb 2017final
Date of last change:2024/09/06
Final SPC
|
common_spc_clean_fenofibrate 215 mg_ WS_ Feb 2017final
Date of last change:2024/09/06
Final SPC
|
common_spc_clean_fenofibrate 67mg_WS_Feb 2017final
Date of last change:2024/09/06
Final SPC
|
common_spc_clean_fenofibrate_160mg_WS_Feb 2017final
Date of last change:2024/09/06
Final PL
|
pl_fenofibrate all strengths_annotated_WS_Feb 2017final
Date of last change:2024/09/06
Final PL
|
pl_fenofibrate all strengths_clean_WS_Feb 2017final
Date of last change:2024/09/06
Final SPC
|
spc_feno all strengths_annotated_WS_Feb 2017final
Date of last change:2024/09/06
Final SPC
|
spc_fenofibrate all strengths_clean_WS_Feb 2017final
Date of last change:2024/09/06
市场状态
Positive
©2006-2024
Drugfuture
->
European Union HMA Authorisation of Medicines DataBase